BTCY Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -17.98% compared to Biotricity, Inc.'s net margin of 14.61%. Biotricity, Inc.'s return on equity of -- beat Electromed, Inc.'s return on equity of 20.35%.

Biotricity, Inc. has a consensus price target of --, signalling upside risk potential of 1598.37%. On the other hand Electromed, Inc. has an analysts' consensus of $37.00 which suggests that it could grow by 58.87%. Given that Biotricity, Inc. has higher upside potential than Electromed, Inc., analysts believe Biotricity, Inc. is more attractive than Electromed, Inc..

Biotricity, Inc. has a beta of -0.134, which suggesting that the stock is 113.355% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.317, suggesting its less volatile than the S&P 500 by 68.266%.

Biotricity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biotricity, Inc. pays 0.36% of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend. Biotricity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biotricity, Inc. quarterly revenues are $4M, which are smaller than Electromed, Inc. quarterly revenues of $18.9M. Biotricity, Inc.'s net income of -$717.1K is lower than Electromed, Inc.'s net income of $2.8M. Notably, Biotricity, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 22.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biotricity, Inc. is 0.40x versus 2.91x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Escalon Medical Corp. has a net margin of -17.98% compared to Biotricity, Inc.'s net margin of 2.72%. Biotricity, Inc.'s return on equity of -- beat Escalon Medical Corp.'s return on equity of -12.94%.

Biotricity, Inc. has a consensus price target of --, signalling upside risk potential of 1598.37%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 7641.94%. Given that Escalon Medical Corp. has higher upside potential than Biotricity, Inc., analysts believe Escalon Medical Corp. is more attractive than Biotricity, Inc..

Biotricity, Inc. has a beta of -0.134, which suggesting that the stock is 113.355% less volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.181, suggesting its less volatile than the S&P 500 by 81.879%.

Biotricity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biotricity, Inc. pays 0.36% of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend. Biotricity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biotricity, Inc. quarterly revenues are $4M, which are larger than Escalon Medical Corp. quarterly revenues of $3.6M. Biotricity, Inc.'s net income of -$717.1K is lower than Escalon Medical Corp.'s net income of $97.7K. Notably, Biotricity, Inc.'s price-to-earnings ratio is -- while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biotricity, Inc. is 0.40x versus 0.15x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guided Therapeutics, Inc. has a net margin of -17.98% compared to Biotricity, Inc.'s net margin of -1236.67%. Biotricity, Inc.'s return on equity of -- beat Guided Therapeutics, Inc.'s return on equity of --.

Biotricity, Inc. has a consensus price target of --, signalling upside risk potential of 1598.37%. On the other hand Guided Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 46666566.67%. Given that Guided Therapeutics, Inc. has higher upside potential than Biotricity, Inc., analysts believe Guided Therapeutics, Inc. is more attractive than Biotricity, Inc..

Biotricity, Inc. has a beta of -0.134, which suggesting that the stock is 113.355% less volatile than S&P 500. In comparison Guided Therapeutics, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.34%.

Biotricity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guided Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biotricity, Inc. pays 0.36% of its earnings as a dividend. Guided Therapeutics, Inc. pays out -- of its earnings as a dividend. Biotricity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biotricity, Inc. quarterly revenues are $4M, which are larger than Guided Therapeutics, Inc. quarterly revenues of $60K. Biotricity, Inc.'s net income of -$717.1K is higher than Guided Therapeutics, Inc.'s net income of -$742K. Notably, Biotricity, Inc.'s price-to-earnings ratio is -- while Guided Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biotricity, Inc. is 0.40x versus 24.64x for Guided Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -17.98% compared to Biotricity, Inc.'s net margin of -1.25%. Biotricity, Inc.'s return on equity of -- beat IRIDEX Corp.'s return on equity of -119.2%.

Biotricity, Inc. has a consensus price target of --, signalling upside risk potential of 1598.37%. On the other hand IRIDEX Corp. has an analysts' consensus of $2.75 which suggests that it could grow by 180.53%. Given that Biotricity, Inc. has higher upside potential than IRIDEX Corp., analysts believe Biotricity, Inc. is more attractive than IRIDEX Corp..

Biotricity, Inc. has a beta of -0.134, which suggesting that the stock is 113.355% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.753, suggesting its less volatile than the S&P 500 by 24.713%.

Biotricity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biotricity, Inc. pays 0.36% of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend. Biotricity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biotricity, Inc. quarterly revenues are $4M, which are smaller than IRIDEX Corp. quarterly revenues of $14.7M. Biotricity, Inc.'s net income of -$717.1K is lower than IRIDEX Corp.'s net income of -$184K. Notably, Biotricity, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biotricity, Inc. is 0.40x versus 0.32x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.